BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Ophthotech Reports Second Quarter 2018 Financial and Operating Results

  (Conference Call and Webcast Today, August 1, 2018, at 8:00 a.m. ET)

  August 1, 2018

   · 

  10 min read
• InMed to Present at the Canaccord Genuity 38th Annual Growth Conference

  InMed Pharmaceuticals Inc. announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston.

  August 1, 2018

   · 

  6 min read
• Business

  Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018

  Aerie Pharmaceuticals, Inc. announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018.

  August 1, 2018

   · 

  2 min read
• Business

  Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018

  Dicerna Pharmaceuticals, Inc. announced that the Company will release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.

  August 1, 2018

   · 

  1 min read
• Biotech Beach

  Forge Achieves CARB-X Milestone To Advance Its LpxC Antibiotic To Treat Infections Caused By The World’s Deadliest ‘Superbugs’

  -Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products-

  August 1, 2018

   · 

  5 min read
• Biotech Beach

  Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene’s Investigational Cancer Drug

  PCM-075 is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor, that is designed to target cell division (mitosis).

  August 1, 2018

   · 

  8 min read
• Genetown

  Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference

  Aldeyra Therapeutics, Inc. announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 at 10:00 AM ET at the InterContinental Hotel, Boston, MA.

  August 1, 2018

   · 

  1 min read
• Biotech Bay

  Xencor to Present at Upcoming August 2018 Investor Conferences

  Xencor, Inc. announced that company management will present at two upcoming conferences

  August 1, 2018

   · 

  2 min read
• Business

  Northern Biologics Strengthens Management Team

  Enda Moran appointed vice president, CMC, and Frédéric Sweeney joins as chief business officer

  August 1, 2018

   · 

  2 min read
• Drug Development

  Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-Small Cell Lung Cancer or Thymic Carcinoma

  This investigator-initiated trial is led by Dr. Leora Horn of the Vanderbilt-Ingram Cancer Center.

  August 1, 2018

   · 

  2 min read